David Rizzieri
Physician · Forsyth Medical Center
Credentials: · · ·
History
2026–Present
- 1994–1996
Medical Oncology
- 1991–1994
Internal Medicine
Research
Journal of Clinical Investigation · 2005 · 768 citations
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Nature · 2009 · 702 citations
Leukemia · 2000 · 675 citations
80 papers
55 papers
48 papers
48 papers
42 papers
33 papers
32 papers
28 papers
Grants
- 2003–2008
Duke/UNC Comprehensive Sickle Cell Center
National Heart, Lung, and Blood Institute · U54
Project lead · $411K · Duke University
- 2000–2005
Mentored Patient-Oriented Research Career Development Aw
National Center for Research Resources · K23
Contact PI · $625.9K · Duke University
Clinical trials
- 2018–2019
Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Principal investigator · Terminated · Phase 1
Eureka Therapeutics Inc.
- 2013–2016
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant
Principal investigator · Completed
Duke University
- 2012–2016
Principal investigator · Completed · Phase 1
Epizyme, Inc.
- 2012–2015
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Principal investigator · Completed · Phase 1
David Rizzieri, MD